-
1
-
-
85009986265
-
-
World Health Organization fact sheet. Hepatitis B. 2015 [cited 13 January, 2016]; Available from
-
[1] World Health Organization fact sheet. Hepatitis B. 2015 [cited 13 January, 2016]; Available from: http://www.who.int/mediacentre/factsheets/fs204/en/.
-
-
-
-
2
-
-
77956639159
-
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
-
[2] Chang, T.T., Liaw, Y.F., Wu, S.S., Schiff, E., Han, K.H., Lai, C.L., et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52 (2010), 886–893.
-
(2010)
Hepatology
, vol.52
, pp. 886-893
-
-
Chang, T.T.1
Liaw, Y.F.2
Wu, S.S.3
Schiff, E.4
Han, K.H.5
Lai, C.L.6
-
3
-
-
84873726484
-
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
-
[3] Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I.M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381 (2013), 468–475.
-
(2013)
Lancet
, vol.381
, pp. 468-475
-
-
Marcellin, P.1
Gane, E.2
Buti, M.3
Afdhal, N.4
Sievert, W.5
Jacobson, I.M.6
-
4
-
-
84872169267
-
Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy
-
[4] Lai, C.L., Yuen, M.F., Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 57 (2013), 399–408.
-
(2013)
Hepatology
, vol.57
, pp. 399-408
-
-
Lai, C.L.1
Yuen, M.F.2
-
5
-
-
0036109092
-
Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication
-
[5] Addison, W.R., Walters, K.A., Wong, W.W., Wilson, J.S., Madej, D., Jewell, L.D., et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 76 (2002), 6356–6363.
-
(2002)
J Virol
, vol.76
, pp. 6356-6363
-
-
Addison, W.R.1
Walters, K.A.2
Wong, W.W.3
Wilson, J.S.4
Madej, D.5
Jewell, L.D.6
-
6
-
-
84940172646
-
HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B
-
[6] Nassal, M., HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64 (2015), 1972–1984.
-
(2015)
Gut
, vol.64
, pp. 1972-1984
-
-
Nassal, M.1
-
7
-
-
84919449705
-
Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance
-
[7] Yang, H.C., Kao, J.H., Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance. Emerg Microbes Infect, 3, 2014, e64.
-
(2014)
Emerg Microbes Infect
, vol.3
-
-
Yang, H.C.1
Kao, J.H.2
-
8
-
-
0032565689
-
Lamivudine therapy of WHV-infected woodchucks
-
[8] Mason, W.S., Cullen, J., Moraleda, G., Saputelli, J., Aldrich, C.E., Miller, D.S., et al. Lamivudine therapy of WHV-infected woodchucks. Virology 245 (1998), 18–32.
-
(1998)
Virology
, vol.245
, pp. 18-32
-
-
Mason, W.S.1
Cullen, J.2
Moraleda, G.3
Saputelli, J.4
Aldrich, C.E.5
Miller, D.S.6
-
9
-
-
0347635488
-
Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy
-
[9] Summers, J., Mason, W.S., Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. Proc Natl Acad Sci USA 101 (2004), 638–640.
-
(2004)
Proc Natl Acad Sci USA
, vol.101
, pp. 638-640
-
-
Summers, J.1
Mason, W.S.2
-
10
-
-
33750964835
-
One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels
-
[10] Wong, D.K., Yuen, M.F., Ngai, V.W., Fung, J., Lai, C.L., One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 11 (2006), 909–916.
-
(2006)
Antivir Ther
, vol.11
, pp. 909-916
-
-
Wong, D.K.1
Yuen, M.F.2
Ngai, V.W.3
Fung, J.4
Lai, C.L.5
-
11
-
-
84880608443
-
Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency
-
[11] Wong, D.K., Seto, W.K., Fung, J., Ip, P., Huang, F.Y., Lai, C.L., et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol 11 (2013), 1004–1010, e1001.
-
(2013)
Clin Gastroenterol Hepatol
, vol.11
, pp. 1004-1010
-
-
Wong, D.K.1
Seto, W.K.2
Fung, J.3
Ip, P.4
Huang, F.Y.5
Lai, C.L.6
-
12
-
-
2942532722
-
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy
-
[12] Werle-Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126 (2004), 1750–1758.
-
(2004)
Gastroenterology
, vol.126
, pp. 1750-1758
-
-
Werle-Lapostolle, B.1
Bowden, S.2
Locarnini, S.3
Wursthorn, K.4
Petersen, J.5
Lau, G.6
-
13
-
-
84928196119
-
Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine
-
[13] Bowden, S., Locarnini, S., Chang, T.T., Chao, Y.C., Han, K.H., Gish, R.G., et al. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol 21 (2015), 4644–4651.
-
(2015)
World J Gastroenterol
, vol.21
, pp. 4644-4651
-
-
Bowden, S.1
Locarnini, S.2
Chang, T.T.3
Chao, Y.C.4
Han, K.H.5
Gish, R.G.6
-
14
-
-
77749308549
-
Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients
-
[14] Lu, H.Y., Zhuang, L.W., Yu, Y.Y., Si, C.W., Virological response to antiviral therapy at week 12 indicates a great reduction of intrahepatic hepatitis B virus DNA and cccDNA in HBeAg-positive chronic hepatitis B patients. J Viral Hepat 17 (2010), 59–65.
-
(2010)
J Viral Hepat
, vol.17
, pp. 59-65
-
-
Lu, H.Y.1
Zhuang, L.W.2
Yu, Y.Y.3
Si, C.W.4
-
15
-
-
33644818518
-
A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
-
[15] Chang, T.T., Gish, R.G., de Man, R., Gadano, A., Sollano, J., Chao, Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006), 1001–1010.
-
(2006)
N Engl J Med
, vol.354
, pp. 1001-1010
-
-
Chang, T.T.1
Gish, R.G.2
de Man, R.3
Gadano, A.4
Sollano, J.5
Chao, Y.C.6
-
16
-
-
33644822860
-
Entecavir vs. lamivudine for patients with HBeAg-negative chronic hepatitis B
-
[16] Lai, C.L., Shouval, D., Lok, A.S., Chang, T.T., Cheinquer, H., Goodman, Z., et al. Entecavir vs. lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006), 1011–1020.
-
(2006)
N Engl J Med
, vol.354
, pp. 1011-1020
-
-
Lai, C.L.1
Shouval, D.2
Lok, A.S.3
Chang, T.T.4
Cheinquer, H.5
Goodman, Z.6
-
17
-
-
37349120537
-
Telbivudine vs. lamivudine in patients with chronic hepatitis B
-
[17] Lai, C.L., Gane, E., Liaw, Y.F., Hsu, C.W., Thongsawat, S., Wang, Y., et al. Telbivudine vs. lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007), 2576–2588.
-
(2007)
N Engl J Med
, vol.357
, pp. 2576-2588
-
-
Lai, C.L.1
Gane, E.2
Liaw, Y.F.3
Hsu, C.W.4
Thongsawat, S.5
Wang, Y.6
-
18
-
-
80051979890
-
Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma
-
[18] Wong, D.K., Huang, F.Y., Lai, C.L., Poon, R.T., Seto, W.K., Fung, J., et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 54 (2011), 829–836.
-
(2011)
Hepatology
, vol.54
, pp. 829-836
-
-
Wong, D.K.1
Huang, F.Y.2
Lai, C.L.3
Poon, R.T.4
Seto, W.K.5
Fung, J.6
-
19
-
-
33748939050
-
Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients
-
[19] Laras, A., Koskinas, J., Dimou, E., Kostamena, A., Hadziyannis, S.J., Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 44 (2006), 694–702.
-
(2006)
Hepatology
, vol.44
, pp. 694-702
-
-
Laras, A.1
Koskinas, J.2
Dimou, E.3
Kostamena, A.4
Hadziyannis, S.J.5
-
20
-
-
0029039362
-
Histological grading and staging of chronic hepatitis
-
[20] Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., et al. Histological grading and staging of chronic hepatitis. J Hepatol 22 (1995), 696–699.
-
(1995)
J Hepatol
, vol.22
, pp. 696-699
-
-
Ishak, K.1
Baptista, A.2
Bianchi, L.3
Callea, F.4
De Groote, J.5
Gudat, F.6
-
21
-
-
20044374023
-
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
-
[21] Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
-
(2005)
Hepatology
, vol.41
, pp. 1313-1321
-
-
Kleiner, D.E.1
Brunt, E.M.2
Van Natta, M.3
Behling, C.4
Contos, M.J.5
Cummings, O.W.6
-
22
-
-
84875241425
-
Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
-
[22] Seto, W.K., Tanaka, Y., Wong, D.K., Lai, C.L., Shinkai, N., Yuen, J.C., et al. Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. Hepatol Int 7 (2012), 98–105.
-
(2012)
Hepatol Int
, vol.7
, pp. 98-105
-
-
Seto, W.K.1
Tanaka, Y.2
Wong, D.K.3
Lai, C.L.4
Shinkai, N.5
Yuen, J.C.6
-
23
-
-
84930387219
-
Management of chronic hepatitis B in patients from special populations
-
[23] Lai, C.L., Yuen, M.F., Management of chronic hepatitis B in patients from special populations. Cold Spring Harb Perspect Med, 5, 2015, a021527.
-
(2015)
Cold Spring Harb Perspect Med
, vol.5
, pp. a021527
-
-
Lai, C.L.1
Yuen, M.F.2
-
24
-
-
33847410055
-
Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels
-
[24] Manesis, E.K., Hadziyannis, E.S., Angelopoulou, O.P., Hadziyannis, S.J., Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther 12 (2007), 73–82.
-
(2007)
Antivir Ther
, vol.12
, pp. 73-82
-
-
Manesis, E.K.1
Hadziyannis, E.S.2
Angelopoulou, O.P.3
Hadziyannis, S.J.4
-
25
-
-
84880939335
-
Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely
-
[25] Chevaliez, S., Hezode, C., Bahrami, S., Grare, M., Pawlotsky, J.M., Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 58 (2013), 676–683.
-
(2013)
J Hepatol
, vol.58
, pp. 676-683
-
-
Chevaliez, S.1
Hezode, C.2
Bahrami, S.3
Grare, M.4
Pawlotsky, J.M.5
-
26
-
-
65449117946
-
Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B
-
[26] Brunetto, M.R., Moriconi, F., Bonino, F., Lau, G.K., Farci, P., Yurdaydin, C., et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 49 (2009), 1141–1150.
-
(2009)
Hepatology
, vol.49
, pp. 1141-1150
-
-
Brunetto, M.R.1
Moriconi, F.2
Bonino, F.3
Lau, G.K.4
Farci, P.5
Yurdaydin, C.6
-
27
-
-
0027131448
-
Relationship between intrahepatic expression of hepatitis B viral antigens and histology in Chinese patients with chronic hepatitis B virus infection
-
[27] Wu, P.C., Lau, J.Y., Lau, T.K., Lau, S.K., Lai, C.L., Relationship between intrahepatic expression of hepatitis B viral antigens and histology in Chinese patients with chronic hepatitis B virus infection. Am J Clin Pathol 100 (1993), 648–653.
-
(1993)
Am J Clin Pathol
, vol.100
, pp. 648-653
-
-
Wu, P.C.1
Lau, J.Y.2
Lau, T.K.3
Lau, S.K.4
Lai, C.L.5
-
28
-
-
57349148151
-
Chronic hepatitis B–new goals, new treatment
-
[28] Lai, C.L., Yuen, M.F., Chronic hepatitis B–new goals, new treatment. N Engl J Med 359 (2008), 2488–2491.
-
(2008)
N Engl J Med
, vol.359
, pp. 2488-2491
-
-
Lai, C.L.1
Yuen, M.F.2
-
29
-
-
68349128691
-
The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion
-
[29] Fung, J., Lai, C.L., Tanaka, Y., Mizokami, M., Yuen, J., Wong, D.K., et al. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol 104 (2009), 1940–1946.
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 1940-1946
-
-
Fung, J.1
Lai, C.L.2
Tanaka, Y.3
Mizokami, M.4
Yuen, J.5
Wong, D.K.6
-
30
-
-
84862664371
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection
-
[30] European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57 (2012), 167–185.
-
(2012)
J Hepatol
, vol.57
, pp. 167-185
-
-
-
31
-
-
79958800541
-
Hepatitis B surface antigen: Relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B
-
[31] Manesis, E.K., Papatheodoridis, G.V., Tiniakos, D.G., Hadziyannis, E.S., Agelopoulou, O.P., Syminelaki, T., et al. Hepatitis B surface antigen: Relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol 55 (2011), 61–68.
-
(2011)
J Hepatol
, vol.55
, pp. 61-68
-
-
Manesis, E.K.1
Papatheodoridis, G.V.2
Tiniakos, D.G.3
Hadziyannis, E.S.4
Agelopoulou, O.P.5
Syminelaki, T.6
-
32
-
-
84883250802
-
High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients
-
[32] Lacombe, K., Boyd, A., Lavocat, F., Pichoud, C., Gozlan, J., Miailhes, P., et al. High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. Hepatology 58 (2013), 912–922.
-
(2013)
Hepatology
, vol.58
, pp. 912-922
-
-
Lacombe, K.1
Boyd, A.2
Lavocat, F.3
Pichoud, C.4
Gozlan, J.5
Miailhes, P.6
-
33
-
-
84920983133
-
Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors
-
[33] van Bommel, F., Bartens, A., Mysickova, A., Hofmann, J., Kruger, D.H., Berg, T., et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology 61 (2015), 66–76.
-
(2015)
Hepatology
, vol.61
, pp. 66-76
-
-
van Bommel, F.1
Bartens, A.2
Mysickova, A.3
Hofmann, J.4
Kruger, D.H.5
Berg, T.6
-
34
-
-
37249092014
-
Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection
-
[34] Wong, D.K., Tanaka, Y., Lai, C.L., Mizokami, M., Fung, J., Yuen, M.F., Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol 45 (2007), 3942–3947.
-
(2007)
J Clin Microbiol
, vol.45
, pp. 3942-3947
-
-
Wong, D.K.1
Tanaka, Y.2
Lai, C.L.3
Mizokami, M.4
Fung, J.5
Yuen, M.F.6
-
35
-
-
84879458710
-
Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation
-
[35] Matsuzaki, T., Tatsuki, I., Otani, M., Akiyama, M., Ozawa, E., Miuma, S., et al. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation. J Gastroenterol Hepatol 28 (2013), 1217–1222.
-
(2013)
J Gastroenterol Hepatol
, vol.28
, pp. 1217-1222
-
-
Matsuzaki, T.1
Tatsuki, I.2
Otani, M.3
Akiyama, M.4
Ozawa, E.5
Miuma, S.6
-
36
-
-
84962605530
-
Hepatitis B virus (HBV) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma
-
[36] Honda, M., Shirasaki, T., Terashima, T., Kawaguchi, K., Nakamura, M., Oishi, N., et al. Hepatitis B virus (HBV) core-related antigen during nucleos(t)ide analog therapy is related to intra-hepatic HBV replication and development of hepatocellular carcinoma. J Infect Dis 213 (2016), 1096–1106.
-
(2016)
J Infect Dis
, vol.213
, pp. 1096-1106
-
-
Honda, M.1
Shirasaki, T.2
Terashima, T.3
Kawaguchi, K.4
Nakamura, M.5
Oishi, N.6
|